

Edwin M Posadas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1748547/publications.pdf>

Version: 2024-02-01

102
papers

3,218
citations

172457

29
h-index

161849

54
g-index

102
all docs

102
docs citations

102
times ranked

5836
citing authors

#	ARTICLE	IF	CITATIONS
1	Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1505403.	12.2	286
2	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017, 3, 1663.	7.1	219
3	Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 73, 422-436.	7.3	200
4	Targeted therapies for renal cell carcinoma. <i>Nature Reviews Nephrology</i> , 2017, 13, 496-511.	9.6	185
5	Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 1344.	7.1	169
6	High-Purity Prostate Circulating Tumor Cell Isolation by a Polymer Nanofiber-Embedded Microchip for Whole Exome Sequencing. <i>Advanced Materials</i> , 2013, 25, 2897-2902.	21.0	142
7	Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring. <i>Nature Communications</i> , 2020, 11, 4489.	12.8	134
8	MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 2306-2317.	0.9	119
9	NanoVelcro Chip for CTC enumeration in prostate cancer patients. <i>Methods</i> , 2013, 64, 144-152.	3.8	107
10	MAOA-Dependent Activation of Shh-IL6-RANKL Signaling Network Promotes Prostate Cancer Metastasis by Engaging Tumor-Stromal Cell Interactions. <i>Cancer Cell</i> , 2017, 31, 368-382.	16.8	102
11	miR-154* and miR-379 in the DLK1-DIO3 MicroRNA Mega-Cluster Regulate Epithelial to Mesenchymal Transition and Bone Metastasis of Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 6559-6569.	7.0	94
12	A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer. <i>Oncotarget</i> , 2015, 6, 44781-44793.	1.8	94
13	Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases. <i>Cancer</i> , 2015, 121, 3240-3251.	4.1	89
14	NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells. <i>Advanced Drug Delivery Reviews</i> , 2018, 125, 78-93.	13.7	89
15	Disparities in Cancer Care and the Asian American Population. <i>Oncologist</i> , 2021, 26, 453-460.	3.7	59
16	Clinical Applications of NanoVelcro Rare-Cell Assays for Detection and Characterization of Circulating Tumor Cells. <i>Theranostics</i> , 2016, 6, 1425-1439.	10.0	56
17	A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. <i>European Urology</i> , 2018, 73, 156-165.	1.9	55
18	Bio-Inspired NanoVilli Chips for Enhanced Capture of Tumor-Derived Extracellular Vesicles: Toward Non-Invasive Detection of Gene Alterations in Non-Small Cell Lung Cancer. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 13973-13983.	8.0	55

#	ARTICLE	IF	CITATIONS
19	Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. <i>Clinical Cancer Research</i> , 2019, 25, 2450-2457.	7.0	52
20	Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2052-2061.	6.4	49
21	Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential. <i>Cancer Research</i> , 2018, 78, 6086-6097.	0.9	49
22	Detection of Live Circulating Tumor Cells by a Class of Near-Infrared Heptamethine Carbocyanine Dyes in Patients with Localized and Metastatic Prostate Cancer. <i>PLoS ONE</i> , 2014, 9, e88967.	2.5	48
23	Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. <i>European Urology</i> , 2021, 79, 762-771.	1.9	47
24	Loss of testosterone impairs anti-tumor neutrophil function. <i>Nature Communications</i> , 2020, 11, 1613.	12.8	40
25	Glycan Stimulation Enables Purification of Prostate Cancer Circulating Tumor Cells on PEDOT NanoVelcro Chips for RNA Biomarker Detection. <i>Advanced Healthcare Materials</i> , 2018, 7, 1700701.	7.6	38
26	Targeting angiogenesis in renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2221-2236.	1.8	37
27	Covalent chemistry on nanostructured substrates enables noninvasive quantification of gene rearrangements in circulating tumor cells. <i>Science Advances</i> , 2019, 5, eaav9186.	10.3	36
28	Cultured circulating tumor cells and their derived xenografts for personalized oncology. <i>Asian Journal of Urology</i> , 2016, 3, 240-253.	1.2	33
29	Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1623-1630.	7.0	33
30	A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2). <i>Clinical Cancer Research</i> , 2020, 26, 3035-3043.	7.0	31
31	Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. <i>Prostate</i> , 2016, 76, 286-293.	2.3	30
32	SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer. <i>Oncotarget</i> , 2015, 6, 44072-44083.	1.8	29
33	S-adenosylmethionine and methylthioadenosine inhibit cancer metastasis by targeting microRNA 34a/b-methionine adenosyltransferase 2A/2B axis. <i>Oncotarget</i> , 2017, 8, 78851-78869.	1.8	27
34	An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 202-210.	3.7	24
35	A phase 2 study of BIND-014 (PSMA-targeted docetaxel nanoparticle) administered to patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 233-233.	1.6	23
36	A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. <i>Theranostics</i> , 2019, 9, 2812-2826.	10.0	20

#	ARTICLE	IF	CITATIONS
37	Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016, 70, 718-721.	1.9	19
38	Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE). <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 25-37.	2.3	19
39	Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis. <i>Nature Communications</i> , 2022, 13, 669.	12.8	19
40	Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma. <i>Case Reports in Urology</i> , 2019, 2019, 1-4.	0.3	17
41	Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 4.e11-4.e17.	1.6	14
42	Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e454-e460.	1.9	14
43	A comparative study of PCS and PAM50 prostate cancer classification schemes. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 733-742.	3.9	14
44	Modulation of cabozantinib efficacy by the prostate tumor microenvironment. <i>Oncotarget</i> , 2017, 8, 87891-87902.	1.8	14
45	Progress and controversies in neoadjuvant therapy. <i>Nature Reviews Urology</i> , 2014, 11, 254-256.	3.8	12
46	Circulating monocytes from prostate cancer patients promote invasion and motility of epithelial cells. <i>Cancer Medicine</i> , 2018, 7, 4639-4649.	2.8	12
47	Cancer epithelia-derived mitochondrial DNA is a targetable initiator of a paracrine signaling loop that confers taxane resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 8515-8523.	7.1	12
48	In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database. <i>European Urology Focus</i> , 2017, 3, 480-486.	3.1	11
49	Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase 1b Study. <i>Clinical Cancer Research</i> , 2020, 26, 3517-3524.	7.0	11
50	Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4819-4832.	2.0	11
51	Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer. <i>Drugs</i> , 2017, 77, 17-28.	10.9	10
52	Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips. <i>Biosensors and Bioelectronics</i> , 2022, 199, 113854.	10.1	10
53	Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 259-271.	2.4	7
54	Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment?. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 425-428.	1.9	7

#	ARTICLE	IF	CITATIONS
55	A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 426-426.	1.6	7
56	Randomized phase II study of sipuleucel-T (SipT) with or without radium-223 (Ra223) in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 130-130.	1.6	7
57	Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database. Cancer, 2016, 122, 222-229.	4.1	6
58	Circulating tumor cells in prostate cancer: beyond enumeration. Clinical Advances in Hematology and Oncology, 2017, 15, 63-73.	0.3	6
59	A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB): Hoosier Oncology Group GU07-122 trial.. Journal of Clinical Oncology, 2012, 30, 4586-4586.	1.6	5
60	Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy.. Journal of Clinical Oncology, 2017, 35, 173-173.	1.6	5
61	Applications of circulating tumor cells for prostate cancer. Asian Journal of Urology, 2016, 3, 254-259.	1.2	4
62	Covalent Chemistry-Mediated Multimarker Purification of Circulating Tumor Cells Enables Noninvasive Detection of Molecular Signatures of Hepatocellular Carcinoma. Advanced Materials Technologies, 2021, 6, 2001056.	5.8	4
63	A phase 1b dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2014, 32, e15562-e15562.	1.6	4
64	Biologic activity of dasatinib administered as neoadjuvant therapy preceding radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 2014, 32, 324-324.	1.6	4
65	An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 113, 278-289.	0.8	4
66	Biology and therapy of urological cancer metastasis. Asian Journal of Urology, 2016, 3, 167-169.	1.2	3
67	RNA Biomarkers: Glycan Stimulation Enables Purification of Prostate Cancer Circulating Tumor Cells on PEDOT NanoVelcro Chips for RNA Biomarker Detection (Adv. Healthcare Mater. 3/2018). Advanced Healthcare Materials, 2018, 7, 1870013.	7.6	3
68	First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?. Drugs, 2022, 82, 439-453.	10.9	3
69	Variation in Communication of Competing Risks of Mortality in Prostate Cancer Treatment Consultations. Journal of Urology, 2022, 208, 301-308.	0.4	3
70	Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2020, 35, 485-489.	1.0	2
71	Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 5025-5025.	1.6	2
72	Luminal and basal subtyping of prostate cancer.. Journal of Clinical Oncology, 2017, 35, 3-3.	1.6	2

#	ARTICLE	IF	CITATIONS
73	Phase Ib study of niraparib plus androgen receptor-targeted therapy (ART) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 122-122.	1.6	2
74	miR-1227 Targets SEC23A to Regulate the Shedding of Large Extracellular Vesicles. Cancers, 2021, 13, 5850.	3.7	2
75	Tumor Cell Isolation: High Purity Prostate Circulating Tumor Cell Isolation by a Polymer Nanofiber-Embedded Microchip for Whole Exome Sequencing (Adv. Mater. 21/2013). Advanced Materials, 2013, 25, 2870-2870.	21.0	1
76	A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer (CRPC): A PCCTC trial.. Journal of Clinical Oncology, 2012, 30, 4654-4654.	1.6	1
77	Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 205-205.	1.6	1
78	Phase 1b study of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2015, 33, 5028-5028.	1.6	1
79	A phase II study of cabozantinib in metastatic castration-resistant prostate cancer (mCRPC) with visceral metastases (VM) with very small nuclear circulating tumor cell (vsnCTC) association studies.. Journal of Clinical Oncology, 2016, 34, 208-208.	1.6	1
80	Prostate cancer CTC-RNA Assay: A new method for contemporary genomics and precision medicine via liquid biopsy.. Journal of Clinical Oncology, 2020, 38, 170-170.	1.6	1
81	Circulating Fatty Objects and Their Preferential Presence in Pancreatic Cancer Patient Blood Samples. Frontiers in Physiology, 2022, 13, 827531.	2.8	1
82	Personalized Therapeutics and Value in Renal Cell Carcinoma: Moving Beyond Lines of Therapy. Journal of Oncology Practice, 2016, 12, 424-425.	2.5	0
83	Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification. Oncology, 2021, 35, 528-535.	0.5	0
84	A translational phase 2 study of cabozantinib in men with metastatic castration resistant prostate cancer with visceral metastases with characterization of circulating tumor cells and large oncosomes.. Journal of Clinical Oncology, 2014, 32, e16080-e16080.	1.6	0
85	Subclassification of prostate cancer circulating tumor cells (CTCs) by nuclear size reveals very-small nuclear CTCs in patients with visceral metastases.. Journal of Clinical Oncology, 2015, 33, 11027-11027.	1.6	0
86	Very small nuclear circulating tumor cell (vsnCTC) as a putative biomarker for visceral metastasis in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, 64-64.	1.6	0
87	A phase 1b/2 study of ibrutinib combination therapy in selected advanced genitourinary and gastrointestinal tumors.. Journal of Clinical Oncology, 2016, 34, TPS2600-TPS2600.	1.6	0
88	A phase 2 study of cabozantinib in metastatic castrate resistant prostate cancer (mCRPC) with visceral metastases (VM) with very small nuclear circulating tumor cell (vsnCTC) association studies.. Journal of Clinical Oncology, 2016, 34, e16552-e16552.	1.6	0
89	Very-small-nuclear circulating tumor cell (vsnCTC) as a putative biomarker for visceral metastasis (VM) in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, e16530-e16530.	1.6	0
90	Luminal and basal subtyping of prostate cancer.. Journal of Clinical Oncology, 2017, 2017, 3-3.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Circulating tumor cell subsets and macrophage polarization to predict efficacy of cabozantinib in advanced prostate cancer with visceral metastases.. Journal of Clinical Oncology, 2017, 35, 5031-5031.	1.6	0
92	NanoVelcro CTC purification systems for expressional analysis of circulating tumor cells from prostate cancer patients.. Journal of Clinical Oncology, 2018, 36, 295-295.	1.6	0
93	Dynamic variations in gene expressions of circulating tumor cells in metastatic castration-resistant prostate cancer patients in response to androgen receptor signaling inhibitors.. Journal of Clinical Oncology, 2018, 36, e17063-e17063.	1.6	0
94	A noninvasive prognostic biomarker for metastatic castration-resistant prostate cancer: Very small nuclear circulating tumor cells.. Journal of Clinical Oncology, 2019, 37, 179-179.	1.6	0
95	A circulating tumor cell RNA assay for dynamic assessment of androgen receptor signaling inhibitors sensitivity in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2019, 37, 157-157.	1.6	0
96	A circulating tumor cell specific RNA assay for assessment of androgen receptor signaling inhibitor sensitivity in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2019, 37, 5059-5059.	1.6	0
97	Digitally captured step counts for evaluating performance status in advanced cancer patients: A single cohort, prospective trial (Digi-STEPS).. Journal of Clinical Oncology, 2019, 37, TPS6651-TPS6651.	1.6	0
98	Association of very small nuclear circulating tumor cell (vsnCTC) with clinical outcomes in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2020, 38, 168-168.	1.6	0
99	The effect of deep AR suppression with enzalutamide or apalutamide on endogenous glucocorticoids: Implications for adverse effects and development of combination therapies.. Journal of Clinical Oncology, 2020, 38, 17-17.	1.6	0
100	Defining the monocyte subset transcriptional signature associated with progression during androgen-target therapy in prostate cancer patients.. Journal of Clinical Oncology, 2020, 38, 157-157.	1.6	0
101	SUN-739 Next Generation AR Antagonists Increase Systemic Active Glucocorticoid Exposure by Altering Glucocorticoid Metabolism. Journal of the Endocrine Society, 2020, 4, .	0.2	0
102	QIM22-198: Optimizing a Systemic Platform to Standardize Oncologic Biosimilars Utilization at Cedars-Sinai Medical Center (CSMC). Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, QIM22-198.	4.9	0